Innate immune response of LTBI+HIV+ children
Innate immune response of LTBI+HIV+ children
批准号:
10263218
负责人:
Ramakrishna Vankayalapati
金额:
$69.51万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-14 至 2024-08-31
关键词:
AdultAgeAntitubercular AgentsBlood specimenCD8-Positive T-LymphocytesCause of DeathCellsCellular ImmunityCessation of lifeChildDefectDevelopmentFOXP3 geneFamilyFutureGenetic PolymorphismGrowthHIVHIV InfectionsHIV/TBHaplotypesHighly Active Antiretroviral TherapyHouseholdHumanIL2RA geneImmuneImmune responseImmune systemImmunityImmunoglobulinsIndiaIndividualInfectionInnate Immune ResponseInvestmentsKiller CellsMeasuresMediatingMemoryMusMycobacterium tuberculosisNatural Killer CellsNaturePatientsPersonsPhenotypePlayPopulationPredispositionProductionProphylactic treatmentPublishingReportingResearchResearch PersonnelResistanceResponse LatenciesRiskRoleSamplingSeriesSiteT cell responseTimeTuberculosisTuberculosis VaccinesVaccinesadaptive immune responsebasecell mediated immune responsechemokinecohortcytokinehigh riskindividual responsemacrophagemonocytenovelpediatric patientspreventreceptorresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Mycobacterium tuberculosis (Mtb) infects one-third of the world’s population and causes almost 1.3 million
deaths per year, including 100, 000 children. Approximately 90% of infected persons have latent tuberculosis
infection (LTBI), have protective immunity and remain well, but 10% develop primary tuberculosis (TB) soon
after infection or reactivation TB many years later. Children are more susceptible to TB infection, due to an
immature immune system. HIV infection in children markedly increases susceptibility to TB, and HIV-infected
persons with LTBI have an 800-fold greater risk of developing active TB (www.cdc.gov/tb/). TB is the leading
cause of death in HIV-infected persons and more than half a million coinfected people die annually. To develop
adequate prophylaxis or therapy, it is important to understand immune responses to Mtb. Identification of HIV+
children with LTBI who are at greatly increased risk for development of TB would allow treating only high-risk
children, facilitating completion of therapy for LTBI and preventing future development of TB. To identify these
children, it is important to pinpoint the nature of the defective immune responses that permit development of
active TB in HIV+LTBI+ pediatric patients.
Over the past 18 years, we have published a series of articles demonstrating that human NK cells have
the potential to contribute to both innate and adaptive immune responses to Mtb. Our recently published
studies demonstrate that memory-like NK cells contribute to vaccine-induced protective immunity against Mtb
and IL-21 is required for expansion of memory-like NK cells in both humans and mice. Based on our
published studies, we hypothesize that HIV-LTBI+ children household contacts have defective
memory-like NK cell expansion compared to HIV-LTBI+ adult household contacts and these defects are
more severe in HIV+ LTBI+ children. The proposed studies in the current application will be performed in
India as a part of RePORT-India consortium. This study will leverage the large Indo-US investment and TB/HIV
research consortium of RePORT-India which has developed cohorts of TB cases and household contacts in
India and has paired Indian investigators with US investigators at 6 sites. Already collected samples will be
used for the proposed studies in aim 1. Our specific aims are: 1. Determine Mtb specific memory-like NK cell
responses of children in a large group of household contacts of TB patients. 2.Compare the memory-like NK
cell responses of HIV+ and HIV- children with LTBI. 3. Determine whether KIR haplotypes and HLA
polymorphism is associated with expansion of memory-like NK cells in children.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Innate immune response of LTBI+HIV+ children
-
批准号:10470320
-
项目类别:
-
资助金额:$69.51万
-
财政年份:2020
-
负责人:Ramakrishna Vankayalapati
-
依托单位:
IFN-γ independent inhibition of MTB growth in human macrophages
-
批准号:9238190
-
项目类别:
-
资助金额:$36.08万
-
财政年份:2017
-
负责人:Ramakrishna Vankayalapati
-
依托单位:
IFN-γ independent inhibition of MTB growth in human macrophages
-
批准号:9913448
-
项目类别:
-
资助金额:$49.52万
-
财政年份:2017
-
负责人:Ramakrishna Vankayalapati
-
依托单位:
Monocyte subpopulation in HIV+LTB+ individuals and development of active TB
-
批准号:9333189
-
项目类别:
-
资助金额:$17.25万
-
财政年份:2016
-
负责人:Ramakrishna Vankayalapati
-
依托单位:
The role of NK cells in HIV and tuberculosis co-infection
-
批准号:8121984
-
项目类别:
-
资助金额:$19.39万
-
财政年份:2011
-
负责人:Ramakrishna Vankayalapati
-
依托单位:
The role of NK cells in HIV and tuberculosis co-infection
-
批准号:8337399
-
项目类别:
-
资助金额:$18.87万
-
财政年份:2011
-
负责人:Ramakrishna Vankayalapati
-
依托单位:
Treg suppression of islet allograft rejection
-
批准号:8477114
-
项目类别:
-
资助金额:$26.24万
-
财政年份:2010
-
负责人:Ramakrishna Vankayalapati
-
依托单位:
Treg suppression of islet allograft rejection
-
批准号:8277367
-
项目类别:
-
资助金额:$27.92万
-
财政年份:2010
-
负责人:Ramakrishna Vankayalapati
-
依托单位:
The mechanisms of regulatory T-cell expansion in human Mycobacterium tuberculosis
-
批准号:8145096
-
项目类别:
-
资助金额:$35.25万
-
财政年份:2010
-
负责人:Ramakrishna Vankayalapati
-
依托单位:
Treg suppression of islet allograft rejection
-
批准号:8664335
-
项目类别:
-
资助金额:$27.92万
-
财政年份:2010
-
负责人:Ramakrishna Vankayalapati
-
依托单位:
The role of regulatory T cells in M. tuberculosis infection
-
批准号:7534987
-
项目类别:
-
资助金额:$17.19万
-
财政年份:2007
-
负责人:Ramakrishna Vankayalapati
-
依托单位:
The role of regulatory T cells in M. tuberculosis infection
-
批准号:7388348
-
项目类别:
-
资助金额:$19.69万
-
财政年份:2007
-
负责人:Ramakrishna Vankayalapati
-
依托单位:
The role of NK cells in human M. Tuberculosis infection
-
批准号:7031660
-
项目类别:
-
资助金额:$26.85万
-
财政年份:2005
-
负责人:Ramakrishna Vankayalapati
-
依托单位:
The role of NK cells in human M. Tuberculosis infection
-
批准号:7337147
-
项目类别:
-
资助金额:$25.58万
-
财政年份:2005
-
负责人:Ramakrishna Vankayalapati
-
依托单位:
The role of NK cells in human M. Tuberculosis infection
-
批准号:7538343
-
项目类别:
-
资助金额:$25.58万
-
财政年份:2005
-
负责人:Ramakrishna Vankayalapati
-
依托单位:
The role of NK cells in human M. Tuberculosis infection
-
批准号:6870025
-
项目类别:
-
资助金额:$25.36万
-
财政年份:2005
-
负责人:Ramakrishna Vankayalapati
-
依托单位:
The role of NK cells in human M. Tuberculosis infection
-
批准号:7152927
-
项目类别:
-
资助金额:$26.08万
-
财政年份:2005
-
负责人:Ramakrishna Vankayalapati
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: